Lyra Therapeutics Inc (LYRA)

Feb 21, 2025

Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace

Feb 21, 2025

Feb 11, 2025

Watch this stock’s price performance: Lyra Therapeutics Inc (NASDAQ:LYRA) - US Post News

Feb 11, 2025

Feb 10, 2025

Lyra Therapeutics Inc (LYRA) receives a Hold rating from Jefferies - Knox Daily

Feb 10, 2025

Feb 10, 2025

Examining the Potential Price Growth of Oshkosh Corp (OSK) - Knox Daily

Feb 10, 2025

Feb 10, 2025

Neuronetics Inc [STIM] Stock sold by Insider Furlong Stephen for $1122.0 - Knox Daily

Feb 10, 2025

Feb 10, 2025

BrightSpire Capital Inc [BRSP] Insider Activity: An Update for Investors - Knox Daily

Feb 10, 2025

Feb 07, 2025

LYRA’s 2023 Market Dance: Down -5.96% – Time to Invest? - The InvestChronicle

Feb 07, 2025

Feb 07, 2025

Lyra Therapeutics Inc (LYRA) Shares Rise Despite Market Challenges - The News Heater

Feb 07, 2025

Feb 07, 2025

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital

Feb 07, 2025

Feb 05, 2025

Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex

Feb 05, 2025

Jan 23, 2025

LYRA News Today | Why did Lyra Therapeutics stock go up today? - MarketBeat

Jan 23, 2025

Jan 18, 2025

Selling Your Galaxy Payroll Group Ltd (GLXG) Stock? Here’s What You Need To Know - Stocks Register

Jan 18, 2025

Jan 18, 2025

New Outlook On ReNew Energy Global plc - Stocks Register

Jan 18, 2025

Jan 18, 2025

Open Lending Corp’s (LPRO) Stock Is Harder To Predict Than You Think - Stocks Register

Jan 18, 2025

Jan 18, 2025

There Is A Lot Of Upside Potential For Helius Medical Technologies Inc(NASDAQ: HSDT) - Stocks Register

Jan 18, 2025

Jan 18, 2025

New Outlook On Vestis Corp - Stocks Register

Jan 18, 2025

Jan 18, 2025

Data-Based Insights About MINISO Group Holding Ltd ADR (MNSO) - Stocks Register

Jan 18, 2025

Jan 11, 2025

Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know - MSN

Jan 11, 2025

Jan 09, 2025

Chronic Rhinosinusitis Without Nasal Polyps Therapeutics - openPR

Jan 09, 2025

Jan 08, 2025

Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN

Jan 08, 2025

Jan 08, 2025

Cidara Therapeutics Announces Leadership Changes and Appointments - MSN

Jan 08, 2025

Jan 06, 2025

Are Investors Keen On Selling Holdings In Phoenix Motor Inc (NASDAQ: PEV)? - Stocks Register

Jan 06, 2025

Jan 05, 2025

State Street Corp Takes Position in Lotus Technology Inc. (NASDAQ:LOT) - Defense World

Jan 05, 2025

Jan 05, 2025

State Street Corp Has $126,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

Jan 05, 2025

Jan 03, 2025

Edible Garden AG Inc (NASDAQ: EDBL): A Stock Worth Watching - Stocks Register

Jan 03, 2025

Jan 02, 2025

Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech

Jan 02, 2025

Dec 15, 2024

Lyra Therapeutics reshuffles board, adjusts director classes - Investing.com

Dec 15, 2024

Dec 15, 2024

Lyra Therapeutics reshuffles board, adjusts director classes By Investing.com - Investing.com UK

Dec 15, 2024

Dec 14, 2024

Lyra Therapeutics, Inc. Announces Board Changes - Marketscreener.com

Dec 14, 2024

Dec 13, 2024

Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 13, 2024

Dec 09, 2024

Lyra Therapeutics Inc’s (NASDAQ: LYRA) Stock Forecast: Increase To $0.5 In A Year - Stocks Register

Dec 09, 2024

Dec 04, 2024

Chronic Rhinosinusitis Without Nasal Polyps Therapeutics Market Size was ~USD 3,930 Million in the 7MM in 2023, estimated DelveInsight - Barchart

Dec 04, 2024

Dec 03, 2024

Incendia Therapeutics Names Healthcare Veteran Brad Smith as CFO, Brings $1B Financing Track Record - StockTitan

Dec 03, 2024

Nov 29, 2024

LYRA (Lyra Therapeutics) GF Score : 43/100 (As of Nov. 29, 2024) - GuruFocus.com

Nov 29, 2024

Nov 26, 2024

Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World

Nov 26, 2024

Nov 18, 2024

William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World

Nov 18, 2024

Nov 18, 2024

HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World

Nov 18, 2024

Nov 14, 2024

Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa

Nov 13, 2024

Nov 13, 2024

Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India

Nov 13, 2024

Nov 13, 2024

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 13, 2024

Nov 12, 2024

Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com

Nov 12, 2024

Nov 12, 2024

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 12, 2024

Nov 12, 2024

Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan

Nov 12, 2024

Nov 01, 2024

Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World

Nov 01, 2024

Oct 29, 2024

Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR

Oct 29, 2024

Oct 23, 2024

Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register

Oct 23, 2024

Oct 16, 2024

Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada

Oct 16, 2024

Oct 15, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times

Oct 15, 2024

Oct 15, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire

Oct 15, 2024